Secondary analysis of the TIME-PRODIGE-28 trial (104 of 139 patients with metastatic colorectal cancer): ctDNA negative before and after FOLFIRI-cetuximab induction was associated with longer PFS (9.6 months) vs ≥80% (3.4) or <80% (2.1) ctDNA decreases (P=0.013).
Secondary analysisn = 104
Boige et al. Circulating Tumor DNA Dynamics and Clinical Outcomes in Patients with Advanced Colorectal Cancer Treated with Cetuximab-Based Induction and Maintenance Treatment